Tudor Investment Corp ET AL Buys New Stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Tudor Investment Corp ET AL bought a new stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 28,553 shares of the biopharmaceutical company's stock, valued at approximately $938,000. Tudor Investment Corp ET AL owned 0.05% of Agios Pharmaceuticals as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in AGIO. Envestnet Asset Management Inc. grew its position in shares of Agios Pharmaceuticals by 3.3% during the 4th quarter. Envestnet Asset Management Inc. now owns 24,805 shares of the biopharmaceutical company's stock worth $815,000 after buying an additional 795 shares during the period. Venturi Wealth Management LLC acquired a new position in Agios Pharmaceuticals during the fourth quarter valued at approximately $33,000. Franklin Resources Inc. acquired a new stake in Agios Pharmaceuticals in the 3rd quarter valued at about $1,499,000. Vanguard Group Inc. lifted its stake in shares of Agios Pharmaceuticals by 1.5% during the 4th quarter. Vanguard Group Inc. now owns 5,631,321 shares of the biopharmaceutical company's stock worth $185,045,000 after buying an additional 85,339 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its holdings in Agios Pharmaceuticals by 48.8% during the 4th quarter. Bank of New York Mellon Corp now owns 265,514 shares of the biopharmaceutical company's stock worth $8,725,000 after purchasing an additional 87,089 shares during the last quarter.

Insiders Place Their Bets

In related news, Director Jacqualyn A. Fouse sold 7,497 shares of the business's stock in a transaction on Thursday, April 10th. The shares were sold at an average price of $25.90, for a total transaction of $194,172.30. Following the completion of the transaction, the director now directly owns 149,220 shares in the company, valued at $3,864,798. The trade was a 4.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 4.30% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. StockNews.com upgraded shares of Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday. Scotiabank decreased their price target on shares of Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating for the company in a research report on Friday, May 2nd. Finally, HC Wainwright initiated coverage on Agios Pharmaceuticals in a report on Monday, February 24th. They set a "buy" rating and a $58.00 target price on the stock. Five investment analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $56.00.

Agios Pharmaceuticals Price Performance

Shares of Agios Pharmaceuticals stock traded up $1.14 during trading on Monday, hitting $28.46. 51,538 shares of the company's stock traded hands, compared to its average volume of 694,564. Agios Pharmaceuticals, Inc. has a 1 year low of $23.42 and a 1 year high of $62.58. The stock has a market capitalization of $1.65 billion, a P/E ratio of 2.53 and a beta of 0.77. The business has a 50-day simple moving average of $29.23 and a 200-day simple moving average of $37.17.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last posted its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($1.55) EPS for the quarter, beating analysts' consensus estimates of ($1.80) by $0.25. The firm had revenue of $8.73 million during the quarter, compared to the consensus estimate of $9.86 million. Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. On average, equities analysts predict that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current fiscal year.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.